Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6-$9.8 Million, Above High End of Revised Guidance
Sanuwave Health (NASDAQ: SNWV) reported preliminary, unaudited Q2 2026 revenue of $9.6 million to $9.8 million, above its revised guidance high end of $9.5 million. The company said this is down about 3% to 5% from $10.1 million in Q2 2025. Results are subject to adjustment after quarter-end close.
How this was made
The 30-second read
Why it matters
The company now expects $9.6-$9.8M, explicitly above the prior revised high end, and cites consumable applicator unit and revenue records as a key positive driver. It also reiterates ongoing headwinds from customer stress and the secondary market for used Ultramist systems, while describing a trade-in program to support certified pre-owned units.
Market read
This is a guidance-to-preliminary-results update for Q2 revenue, which can materially shift expectations for the upcoming August earnings release and near-term valuation for SNWV.
What to watch
Management attributes headwinds to customer stress and used-system sales cannibalization, so traders should watch whether consumables record sales can offset system placement softness in the final quarter numbers.
Background
Sanuwave previously revised Q2 2026 revenue guidance to $8.5-$9.5M on June 16, 2026, and this release provides preliminary, unaudited results for the quarter ended June 30, 2026.
Ticker impact
Sanuwave guided Q2 2026 revised revenue to $8.5-$9.5M, but now expects $9.6-$9.8M, above the prior high end.
Likely near-term positive bias for SNWV as traders reprice the probability of a stronger Q2 print and better consumables trajectory.
The article discloses a fresh, management-provided revenue range and explicitly frames it as above revised guidance, which is a direct earnings-read-through catalyst. However, it is preliminary and unaudited, so magnitude and follow-through remain uncertain.
Market effects
Directed energy wound care names may see read-across interest if consumables-driven razor-razorblade dynamics appear to be strengthening.
No specific regional market impact indicated beyond US small-cap biotech/medtech sentiment.
Limited global relevance; story is company-specific with no international regulatory or distribution changes mentioned.
Counterpoint
The beat may be driven by timing or one-off factors (e.g., used Ultramist trade-in dynamics) and could reverse by quarter-end close or in the final audited results.
Key entities
- companySanuwave Health, Inc.
NASDAQ-listed directed energy wound care systems and consumables provider issuing preliminary Q2 2026 revenue guidance update.
- personMorgan Frank
CEO quoted on Q2 performance, including consumables record sales and system sales headwinds.
